(lp0
S"Shire's $5.9 Billion Acquisition of Dyax Helps Eliminate a Rival Bloomberg - Nov 2, 2015 Shire Plc, whose $30 billion bid to acquire Baxalta Inc. was rebuffed, is buying biotechnology company Dyax Corp. for at least $5.9 billion in cash to gain a promising treatment for a rare genetic disorder and eliminate a key competitor.Shire  to Acquire Dyax Corp  in $5.9B Deal - StreetInsider.comShire to Acquire Dyax for Up to $6.5 Billion - Wall Street Journal"
p1
aS'Investing With An Edge: Dyax Corp. Seeking Alpha - Dec 7, 2015 DYAX is getting acquired by Shire  for $37.30 per share, plus a non-tradeable CVR that will pay $4 in cash per share if DX-2930 is approved by the FDA before the end of 2019.'
p2
aS'3 Reasons to Avoid Dyax Corp. Stock Motley Fool - Aug 29, 2015 Dyax Corp.  recently reported solid Q2 earnings, with encouraging updates on its major initiatives .'
p3
aS'4 Key Updates We Just Heard from Dyax Corp. Motley Fool - Jul 30, 2015 Dyax Corp  reported earnings and clinical updates yesterday after the bell yesterday in a very interesting call that displayed how the company is rapidly working to diversify.'
p4
aS"Is Dyax Corp. Stock Worth Buying? Motley Fool - Sep 21, 2015 Truth be told, though, most of the appreciation in Dyax's share price occurred in a single day back in April. Specifically, Dyax's share price immediately rose by an astounding 50% following the company's announcement that its experimental treatment ..."
p5
aS'Shire Completes Acquisition of Dyax PR Newswire  - Jan 22, 2016 Shire plc  today announced that it has completed its acquisition of Dyax Corp.  in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.'
p6
aS'Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy ... Business Wire  - Nov 9, 2015 BURLINGTON, Mass.----Dyax Corp.  today announced that two oral presentations describing clinical data from its DX-2930 Phase 1b study were presented at the American College of Allergy, Asthma, and Immunology&nbsp;...'
p7
aS'Dyax Corp  Announces Positive Results from Phase 1b Trial of DX-2930 and ... StreetInsider.com - Mar 31, 2015 Dyax Corp.  today announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930.Oppenheimer Boosts Price Target for Dyax Corp. as DX-2930 Data Results ... - Smarter AnalystDyax  Stock: Meteoric Rally After Blowout Clinical Trial - Investorplace.com'
p8
aS"Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology ... Business Wire  - Dec 6, 2015 BURLINGTON, Mass.----Dyax Corp.  today announced a poster presentation describing preclinical data for DX-4012, the Company's fully human monoclonal antibody to activated Factor XII , was presented at&nbsp;..."
p9
aS'Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for ... Business Wire  - Jul 7, 2015 BURLINGTON, Mass.----Dyax Corp.  today announced that the U.S. Food and Drug Administration  granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema .Dyax Hereditary Angioedema Drug Gets Breakthrough Status - Zacks.com'
p10
a.